High BRAF mutation frequency does not characterize all melanocytic tumor types.

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Cutaneous melanoma (CM) is a lethal skin cancer.
• BRAF and NRAS mutations are frequently observed in CM and some benign melanocytic tumors.
• The necessity of these mutations for all melanocytic neoplasia remains unclear.

Purpose of the Study:

• To investigate the frequency of BRAF and NRAS mutations across various melanocytic tumor types.
• To assess the activity of the MAPK pathway in tumors with low BRAF/NRAS mutation rates.
• To determine if BRAF/NRAS mutations are essential for melanocytic tumor development.

Main Methods:

• Screening of 79 melanocytic tumors for BRAF and NRAS mutations.
• Immunohistochemistry analysis of MAPK pathway activation (phosphorylated ERK1/2) in a subset of tumors.
• Statistical analysis to compare mutation frequencies across different tumor types.

Main Results:

• Significant differences in BRAF exon 15 mutation frequency were observed: high in common acquired nevi (87.5%) and CMs (75%), but absent in Spitz nevi and low in blue nevi (12%).
• NRAS mutations were infrequent across all tumor types studied.
• Spitz nevi exhibited strong MAPK pathway activation despite low BRAF/NRAS mutation rates, while blue nevi showed weak activation.

Conclusions:

• BRAF and NRAS mutations are not universally required for the development of all melanocytic tumors.
• Spitz nevi and potentially other tumor types may arise through alternative molecular mechanisms.
• Understanding these alternative pathways is crucial for comprehensive diagnosis and treatment of melanocytic neoplasia.